CAR-T Therapy in Early Lines of R/R MM: Clinical Scenario Discussion and Key Takeaways
Panelists discuss successful collaborations between academic centers and community practices in the context of (chimeric antigen receptor (CAR) T-cell therapy for multiple myeloma, key lessons learned in integrating CAR T therapy into the treatment landscape, and future plans for expanding CAR T therapy’s role in earlier lines of multiple myeloma treatment.
EP: 1.Exploring CAR-T Therapy in Early Lines of Relapsed/Refractory Multiple Myeloma
EP: 2.Patient Selection and Referral Eligibility for CAR-T Therapy
EP: 3.Understanding the CAR-T Treatment Process
EP: 4.CAR-T Therapy: Approach to Bridging
EP: 5.Care Coordination and Transition Strategies for CAR-T Therapy
EP: 6.CAR-T Therapy in Early Lines of R/R MM: Clinical Scenario Discussion and Key Takeaways
EP: 7.Key Takeaways in CAR-T Therapy for Multiple Myeloma
Video content above is prompted by the following:
- Can you share any examples of successful collaborations between your academic center and community practices in the context of CAR-T therapy for multiple myeloma?
- What are the most important lessons your institution has learned in the integration of CAR-T therapy into the multiple myeloma treatment landscape?
- Looking ahead, what are your institution’s plans or considerations for further expanding the role of CAR-T therapy into earlier lines of multiple myeloma treatment?
![“Every patient [with multiple myeloma] should be offered CAR T before they’re offered a bispecific, with some rare exceptions,” said Barry Paul, MD.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F70a5f0fed7009863fe30cf0740cf32014ebaf5be-2974x1660.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30 "“Every patient [with multiple myeloma] should be offered CAR T before they’re offered a bispecific, with some rare exceptions,” said Barry Paul, MD.")
Navigating AE Management for Cellular Therapy Across Hematologic Cancers
A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.
Prolaris in Practice: Guiding ADT Benefits, Clinical Application, and Expert Insights From ACRO 2025
April 15th 2025Steven E. Finkelstein, MD, DABR, FACRO discuses how Prolaris distinguishes itself from other genomic biomarker platforms by providing uniquely actionable clinical information that quantifies the absolute benefit of androgen deprivation therapy when added to radiation therapy, offering clinicians a more precise tool for personalizing prostate cancer treatment strategies.
